Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Prime Medicine, Inc. (PRME)
NASDAQ:PRME
RESEARCH TOOLSreports
Holding PRME?
Track your performance easily
PRME Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.56 - $9.77
Previous CloseN/A
Volume144.88K
Average Volume (3M)1.10M
Market Cap
$376.43M
Enterprise Value$329.21M
Total Cash (Recent Filing)$53.33M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.91
Next Earnings
Mar 06, 2025EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.01
Shares Outstanding131,160,840
10 Day Avg. Volume790,999
30 Day Avg. Volume1,103,614
Standard Deviation0.19
R-Squared0.15
Alpha-0.08
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)470.54
Price to Cash Flow (P/CF)-3.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue340.09
Enterprise Value/Gross Profit1.96K
Enterprise Value/Ebitda-1.68
Forecast
1Y Price Target
$10.83Price Target Upside274.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Prime Medicine, Inc. News
PremiumCompany Announcements
Prime Medicine Advances Gene Editing and Trials
PremiumCompany Announcements
Prime Medicine Reports Q3 2024 Financial Progress
PremiumPre-Earnings
Is PRME a Buy, Before Earnings?
PremiumCompany Announcements
Prime Medicine Advances Gene Editing for Liver DiseasesBulls Say, Bears Say
Bulls Say
Market OpportunitiesPM577 for Wilson's Disease represents a significant market opportunity due to high unmet need and promising preclinical data.
Strategic PartnershipsPrime Medicine recently announced a strategic research collaboration and license agreement with Bristol Myers Squibb, receiving $110 million upfront with the potential for more than $3.5 billion in milestone payments.
Technological AdvancementsPrime Editing-based therapies enable editing, correcting, inserting, and deleting DNA sequences for an unprecedented range of tissues and genes, unlocking several indications not covered by other editing technologies.
Bears Say
Financial PerformancePRME reported a Q3 net loss of $53MM despite the upfront infusion from the research collaboration with BMS.
Market ValuationKey hold-ups in the editing space in terms of market valuation include the risk around long term safety data in patients and expansion into in vivo settings.
Uncertainty In DevelopmentsThere is no guidance on the timing for IND/CTA for CYBB targeted gene therapy, creating uncertainty about future developments.
---
Ownership Overview
42.74% Insiders
8.18% Mutual Funds
0.34% Other Institutional Investors
39.06% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $2.56 and its highest was $9.77 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $376.43M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Mar 06, 2025 which is in 44 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.44 earnings per share for the quarter, missing the consensus estimate of -$0.385 by -$0.055.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. does not currently pay dividends.
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 131,160,840 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.44 in its last earnings report, missing expectations of -$0.385. Following the earnings report the stock price went down -8.333%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
---
Prime Medicine, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.83 (274.74% Upside)
$10.83 (274.74% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 83%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 527.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.50%
12-Months-Change
Fundamentals
Return on Equity
-114.35%
Trailing 12-Months
Asset Growth
39.16%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs.
---
PRME Stock 12 Month Forecast
Average Price Target
$10.83
▲(274.74% Upside)
Technical Analysis
Beam Therapeutics
―
Meiragtx Holdings
―
Voyager Therapeutics
―
Crispr Therapeutics AG
―
Sangamo Biosciences
―
Verve Therapeutics
―
Best Analysts Covering PRME
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-30.63%
assigned a buy rating 2 months ago
Copying Soumit Roy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -30.63% per trade.
---